Literature DB >> 22307765

Prognostic significance of T cell subsets in peripheral blood of B cell non-Hodgkin's lymphoma patients.

Mehdi Dehghani1, Shokouh Sharifpour, Zahra Amirghofran, Hamid Reza Zare.   

Abstract

The role of tumor-infiltrating T cell subsets in the prognosis of non-Hodgkin's lymphoma (NHL) has previously been reported. In the present study, we investigated the prognostic significance of different T cell subsets in the peripheral blood of NHL patients. Immunophenotyping was performed on the peripheral blood samples of 45 patients with newly diagnosed B cell NHL using flow cytometry. The relationship between T cell subsets of CD4+, CD8+, CD3+CD25+, CD4+CD25+, CD4+CD25high [as T regulatory cells (T reg)], and the CD4/CD8 ratio with international prognostic index (IPI) and response to therapy was determined. The percentages of CD3+, CD4+, and CD8+ T cells in the peripheral blood of the patients were 49.1±20.3%, 23.6±11%, and 31.4±14.4%, respectively (CD4/CD8 ratio: 0.92±0.6). There were 4.2±3.2% T reg cells. A study of the percentage of T cells in relation to IPI score showed a higher proportion of CD3+CD25+, CD4+, and CD4+CD25+ cells in low-risk patients compared with intermediate/high risk groups (p<0.05). The above cells, as well as CD4+CD25high T reg cells, indicated a positive correlation with complete remission (CR) and survival. CD4 positivity correlated significantly with survival and CR durations, which were longer in patients with ≥20% CD4+ cells than those with <20% CD4+ cells, thus indicating the prognostic value of CD4+ T cells in NHL patients. There was no significant data on CD8+ cells as well as the CD4/CD8 ratio between distinct IPI groups and response to therapy. These data indicated the importance of CD4+ cells and the activation status of T cells in immunity against lymphoma and the prognostic implication of enumeration of these cells in NHL patients.

Entities:  

Mesh:

Year:  2012        PMID: 22307765     DOI: 10.1007/s12032-012-0176-1

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  28 in total

1.  Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma.

Authors:  Anastasios Chatzitolios; Ioannis Venizelos; Gregory Tripsiannis; George Anastassopoulos; Nikolaos Papadopoulos
Journal:  Ann Hematol       Date:  2010-03-30       Impact factor: 3.673

Review 2.  Altered immunity as a risk factor for non-Hodgkin lymphoma.

Authors:  Andrew E Grulich; Claire M Vajdic; Wendy Cozen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03-02       Impact factor: 4.254

3.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

4.  Primary T-cell lymphoma of the breast with lymphoepithelial lesion. A case report.

Authors:  M Vasei; P V Kumar; S A Malekhosseini; Z Amirghofran
Journal:  APMIS       Date:  1997-06       Impact factor: 3.205

Review 5.  Targeting Foxp3+ regulatory T cells-related immunosuppression for cancer immunotherapy.

Authors:  Li-Li Feng; Xin Wang
Journal:  Chin Med J (Engl)       Date:  2010-11       Impact factor: 2.628

Review 6.  Regulatory T cells in cancer.

Authors:  Marc Beyer; Joachim L Schultze
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

7.  Can CD3+/HLA-DR+ activated T cells predict the prognosis of non-Hodgkin's lymphoma patients?

Authors:  László Váróczy; Lajos Gergely; Zsófia Miltényi; Magdolna Aleksza; Arpád Illés
Journal:  Immunol Lett       Date:  2005-02-15       Impact factor: 3.685

8.  Immunobiologic factors predictive of clinical outcome in diffuse large-cell lymphoma.

Authors:  D J Slymen; T P Miller; S M Lippman; C M Spier; D P Kerrigan; J A Rybski; C S Rangel; L C Richter; T M Grogan
Journal:  J Clin Oncol       Date:  1990-06       Impact factor: 44.544

9.  [CD4+CD25+T regulatory cells in peripheral blood of B-NHL patients with or without chemotherapy].

Authors:  Yan-Xia Shi; Xiao-Shi Zhang; Dong-Geng Liu; Yong-Qiang Li; Zhong-Zhen Guan; Wen-Qi Jiang
Journal:  Ai Zheng       Date:  2004-05

10.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Authors:  Alexandar Tzankov; Cecile Meier; Petra Hirschmann; Philip Went; Stefano A Pileri; Stephan Dirnhofer
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

View more
  10 in total

Review 1.  CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma.

Authors:  Gunilla Enblad; Hannah Karlsson; Angelica S I Loskog
Journal:  Hum Gene Ther       Date:  2015-08       Impact factor: 5.695

2.  Dissecting the regulatory microenvironment of a large animal model of non-Hodgkin lymphoma: evidence of a negative prognostic impact of FOXP3+ T cells in canine B cell lymphoma.

Authors:  Dammy Pinheiro; Yu-Mei Chang; Hannah Bryant; Balazs Szladovits; Tim Dalessandri; Lucy J Davison; Elizabeth Yallop; Emily Mills; Chiara Leo; Ana Lara; Anneliese Stell; Gerry Polton; Oliver A Garden
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

3.  A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy.

Authors:  Chang-Juan Tao; Yuan-Yuan Chen; Feng Jiang; Xing-Lai Feng; Qi-Feng Jin; Ting Jin; Yong-Feng Piao; Xiao-Zhong Chen
Journal:  Oncotarget       Date:  2016-07-19

4.  Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia - a randomized controlled trial.

Authors:  Yun Lin; Zhuang Miao; Yue Wu; Fang-Fang Ge; Qing-Ping Wen
Journal:  BMC Anesthesiol       Date:  2019-12-19       Impact factor: 2.217

5.  A 4-gene-based hypoxia signature is associated with tumor immune microenvironment and predicts the prognosis of pancreatic cancer patients.

Authors:  Jianfeng Ding; Xiaobo He; Xiao Cheng; Guodong Cao; Bo Chen; Sihan Chen; Maoming Xiong
Journal:  World J Surg Oncol       Date:  2021-04-17       Impact factor: 2.754

6.  An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma.

Authors:  Yuanshuai Li; Xiaofang Sun
Journal:  Front Genet       Date:  2022-03-16       Impact factor: 4.599

7.  Peripheral lymphocyte populations in ovarian cancer patients and correlations with clinicopathological features.

Authors:  Shuang Ye; Wei Chen; Yuwei Zheng; Yutuan Wu; Libing Xiang; Teng Li; Bo Ping; Xiaoming Zhang; Huijuan Yang
Journal:  J Ovarian Res       Date:  2022-04-11       Impact factor: 4.234

8.  Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma.

Authors:  Yan-Li Li; Kang-Sheng Gu; Yue-Yin Pan; Yang Jiao; Zhi-Min Zhai
Journal:  BMC Cancer       Date:  2014-05-19       Impact factor: 4.430

9.  Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer.

Authors:  María Del Mar Valenzuela-Membrives; Francisco Perea-García; Abel Sanchez-Palencia; Francisco Ruiz-Cabello; Mercedes Gómez-Morales; María Teresa Miranda-León; Inmaculada Galindo-Angel; María Esther Fárez-Vidal
Journal:  Oncotarget       Date:  2016-11-01

10.  An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy.

Authors:  Yaxiao Lu; Jingwei Yu; Wenchen Gong; Liping Su; Xiuhua Sun; Ou Bai; Hui Zhou; Xue Guan; Tingting Zhang; Lanfang Li; Lihua Qiu; Zhengzi Qian; Shiyong Zhou; Bin Meng; Xiubao Ren; Xianhuo Wang; Huilai Zhang
Journal:  Front Oncol       Date:  2021-07-13       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.